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Driving and Implantable
Cardioverter-Defibrillator
Shocks for Ventricular Arrhythmias
Results From the TOVA Study
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Objectives This study examined the risk of implantable cardioverter-defibrillator (ICD) shocks for ventricular tachycardia (VT)
or ventricular fibrillation (VF) associated with driving.
Background Concerns regarding VT/VF occurring during driving are the basis for driving restrictions in ICD patients; however,
limited data are available to inform recommendations.
Methods This study used a prospective nested case-crossover design to compare the risk of ICD shock for VT/VF both dur-
ing and up to 60 min after an episode of driving as compared with that during other activities among 1,188 ICD
patients enrolled in the TOVA (Triggers of Ventricular Arrhythmia) study.
Results Over a median follow-up of 562 days, there were 193 ICD shocks for VT/VF with data on exposure to driving be-
fore ICD shock. The absolute risk of ICD shock for VT/VF within 1 h of driving was estimated to be 1 episode per
25,116 person-hours spent driving. The ICD shocks for VT/VF were twice as likely to occur within 1 h of driving a
car as compared with other times (relative risk [RR] 2.24, 95% confidence interval [CI] 1.57 to 3.18). This risk
was specific for shocks for VT/VF and occurred primarily during the 30-min period after driving (RR 4.46, 95% CI
2.92 to 6.82) rather than during the driving episode itself (RR 1.05, 95% CI 0.48 to 2.30).
Conclusions Although the risk of ICD shock for VT/VF was transiently increased in the 30-min period after driving, the risk
was not elevated during driving and the absolute risk was low. These data provide reassurance that driving by
ICD patients should not translate into an important rate of personal or public injury. (J Am Coll Cardiol 2007;
50:2233–40) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.059p
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gudden death from cardiac causes has been known to occur
uring driving, but it is unclear whether a causal relationship
xists. In one study (1), 71 (5%) of 1,348 coronary heart disease
eaths occurred while driving. Driving a car can be a moder-
tely stressful activity for some, and psychological stress is
elieved to trigger life-threatening ventricular arrhythmias
2–4). Driving a car is also accompanied by exposure to
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L041016) and from the Guidant Foundation, Guidant Cardiac Rhythm Management.
Sarticulate air pollution (5), and a large number of epidemio-
ogic studies have found an association between short-term
See page 2241
ncreases in particulate air pollution and cardiovascular mor-
idity and mortality (6–8). Recently, acute exposure to traffic
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Driving and ICD Shocks for VT/VF December 4, 2007:2233–40has also been associated with onset
of myocardial infarction (MI) (9),
but to our knowledge, no studies
have examined the impact of driv-
ing on ventricular arrhythmias.
Because driving an automobile
is not only a quality-of-life issue
(10), but also is considered by
many to be a basic necessity,
knowledge about the incidence
and risk of ventricular arrhyth-
mias during driving is of direct
clinical and public health impor-
tance. It is a well-recognized con-
ern that patients with implantable cardioverter-defibrillators
ICDs) may experience life-threatening ventricular arrhyth-
ias while driving, and the resultant loss of consciousness
ay result in injury to the patient, other passengers, and
ystanders (11). Physicians who care for these patients must
alance these risks when making recommendations regard-
ng driving. However, there are limited data to adequately
nform recommendations (12). Data from the AVID (An-
iarrhythmics Versus Implantable Defibrillators) trial re-
orted that 8% of patients experienced an ICD shock while
riving (13), although it was unclear from these data
hether a causal relationship existed. The TOVA (Triggers
f Ventricular Arrhythmias) study presented a unique op-
ortunity to examine these risks and further define the
elationship between driving a car and the occurrence of
entricular arrhythmias among susceptible patients with
CDs.
ethods
atient population. The TOVA study is a multicenter
rospective cohort study designed to identify lifestyle and
sychological triggers of ICD shock for ventricular tachy-
ardia (VT) and/or ventricular fibrillation (VF). From June
, 2000, to March 21, 2003, 1,188 patients with ICDs were
nrolled at the time of implantation or through the ICD
linics at 31 participating centers in the U.S. To qualify for
nrollment, patients had to meet the 1998 American Col-
ege of Cardiology/American Heart Association guidelines
or ICD implantation (14) (Class I to IIB indications),
hich included the following: 1) cardiac arrest; 2) sponta-
eous sustained ventricular tachycardia; 3) primary or re-
urrent syncope with inducible VT refractory to drug
herapy; 4) nonsustained ventricular tachycardia with coro-
ary disease, prior MI, left ventricular dysfunction, and
nducible sustained VT or VF; or 5) familial or inherited
ondition with high risk of life-threatening arrhythmia.
tudy design. We used a nested case-crossover design to
uantify the relative risk (RR) of an ICD shock for VT/VF
uring or up to 60 min after an episode of driving as
ompared with the risk during other activities (Fig. 1). The
Abbreviations
and Acronyms
CI  confidence interval
ICD  implantable
cardioverter-defibrillator
MET  metabolic
equivalent
MI  myocardial infarction
RR  relative risk
VF  ventricular fibrillation
VT  ventricular
tachycardiaase-crossover study design assesses the change in risk of an ocute event during a brief hazard period during and/or after
xposure to a transient risk factor (15). For each individual
CD shock, the prospectively collected prior habitual fre-
uency of driving for that participant served as the control
nformation, and a self-matched analysis was conducted.
ssessment of control exposures. At entry into the study,
he study staff at each clinical site collected information on
aseline clinical characteristics from the patient’s medical
ecord using a structured data abstraction form and inter-
iewed patients regarding demographics, cardiac symptoms,
ifestyle habits, and medications via standardized question-
aires. During this baseline interview, participants also were
sked to report their usual frequency of participating in
arious activities, experiencing certain emotions, and expo-
ure to other potential triggers. Updated information on
sual frequency of exposures was collected with similar
uestionnaires at 6 and 12 months of follow-up.
Exposure to driving was ascertained with the following
uestions at baseline and at 6 months and 12 months of
ollow-up: “Since implantation or over the past 6 months,
n average, how often do you drive a car?” and “On average,
ow long do you drive each time?” Responses to these
uestions were open ended. Calculation of exposed person-
ime depended on the hazard period examined. In the
rimary analysis, exposed person-time was calculated by
dding 60 min to the reported usual duration of driving and
ultiplying this sum by the reported frequency of driving in
he past 6 months. When examining the components of the
azard period, only the time spent in that particular portion
f the hazard period was considered exposed. To calculate
nexposed person-time, exposed person-time in hours was
ubtracted from the number of hours in the 6-month
nterval or the amount of time since enrollment if the shock
Exposed
Driving
17.5 30           30
Not Driving Not Driving
Not Exposed Not Exposed
A B          C
Figure 1 Hazard Periods for Case-Crossover Analysis
The green-shaded portion of the timeline represents the hazard period during
or after a driving episode. If an implantable cardioverter-defibrillator (ICD) dis-
charge occurred during this window, the patient was considered exposed in the
primary analysis. In secondary analyses, we examined the relative risk of ICD
discharge within the 3 separate shaded components of the hazard period: the
period during driving (A), the first 30-min interval (B), and the second 30-min
interval (C) after a driving episode.ccurred within the first 6 months of the study.
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December 4, 2007:2233–40 Driving and ICD Shocks for VT/VFssessment of case exposures. After entry into the study,
atients were followed up for ICD discharges by the study
nd clinical staff at participating institutions. To allow the
idest range of patients to be included in the study, we did
ot pre-specify how the ICD should be programmed, but
nstead chose to defer to physician judgment to use clinical
tandards of care. Patients were asked to call the staff within
2 h of experiencing an ICD shock. Participants were then
nterviewed about lifestyle and psychological exposures oc-
urring within the minutes, hours, and days preceding ICD
hock. To minimize bias in ascertainment, interviewers and
atients were not informed of the hypothesized hazard
eriod. Exposure to driving was ascertained with the fol-
owing question: “Before the device discharged, when was
he last time you drove?” There were 9 possible response
ategories ranging from “at the time of the shock” to “5 or
ore days before.” Participants who reported driving at the
ime of, one-half hour before, or 1 h before the shock were
onsidered exposed.
ase/end point confirmation. Stored electrograms were
ownloaded from the patient’s ICD by the clinical centers at
he patient’s first post-shock visit and during routine clinic
isits on a 3- to 6-month basis. Electrograms were then
eviewed at the central core laboratory by electrophysiolo-
ists blinded to exposure status. The date and time of
ischarge, the type and number of therapies, and the
resence and type of underlying arrhythmia were deter-
ined. The primary analysis included only appropriate ICD
hocks for ventricular arrhythmias, but secondary analyses
ere also performed for inappropriate shocks.
tatistical analyses. Means or proportions of baseline de-
ographics and clinical characteristics were computed for
he entire cohort across 4 categories of increasing driving
requency, and the significance of associations was tested
sing the Mantel-Haenszel chi-square test for trend for
ategorical variables and linear regression for continuous
ariables.
For the case-crossover analysis, each ICD shock serves as
n individual case and the control information is based on
he usual amount of driving reported on the most recent
uestionnaire before the shock. The analysis of case-
rossover data is similar to that of a crossover experiment
ut with varying exposure times, in which each individual’s
isk is assessed during periods of exposure and nonexposure
nd each individual serves as both a case and control
self-matching). We computed the incidence rate ratio as a
easure of RR for the association between driving and
pisodes of VT/VF using the Mantel-Haenszel estimator
or sparsely distributed person-time data using each indi-
idual as the stratifying variable. In this analysis, each
ubject’s person-time was categorized into periods of expo-
ure and nonexposure as previously described (15–17). The
ata were then stratified by each individual shock and were
nalyzed using methods for cohort studies with sparse data
n each stratum (17). pThe pre-specified hazard period for the primary analysis
as the time spent driving and up to 60 min after each
pisode. In secondary analyses, we examined the risk during
riving and 30-min intervals after a driving episode (Fig. 1).
everal sensitivity analyses were also performed. To explore
he possibility of intraindividual confounding, sensitivity
nalyses excluding patients who were exposed to at least
oderate levels of exertion (5 metabolic equivalents
METs]) as quantified on a scale of 1 to 6 METs (18) or
oderate levels of anger within 1 h of ICD shock were
erformed. To investigate the sensitivity of our result to
epeated shocks in the same patient, we repeated the
nalysis only including the first shock experienced by each
atient. Finally, because patients are unlikely to drive during
he nighttime hours between 12 AM to 6 AM when the risk
f an ICD shock is lowest (19,20), we performed a sensi-
ivity analysis that excluded this nighttime period from the
ase-crossover analysis. In this analysis, we conservatively
ssume that none of the patients were exposed to driving
uring this time period. Potential modifiers of the RR were
valuated by comparing RRs in categories of the modifier
nd then comparing these RRs with the chi-square test for
omogeneity (21). All reported p values are 2-sided. Statis-
ical analyses were performed using SAS software version
.1 (SAS Institute Inc., Cary, North Carolina).
esults
mong the 1,188 patients enrolled in the TOVA study,
,106 patients provided information on their driving habits
t entry into the study (Table 1). The majority of patients
80%) reported driving a car at least once per week. Overall,
articipants reported spending a median of 3.8 h/week
interquartile range 1.2 to 7.7 h/week) or 2.3% (interquartile
ange 0.7% to 4.6%) of their time driving a car. Those who
rove more frequently were younger, more educated, and
ore likely to be men or Caucasian. They also tended to be
ealthier and were less likely to have diabetes, hypertension,
ongestive heart failure, or a left ventricular ejection fraction
ower than 30%. With respect to current recommendations
egarding driving, patients who recently underwent ICD
mplantation tended to drive less (p  0.08). However, of
hose with recent implants, 75.1% reported driving at least
nce per week and 38.6% were driving more than 2 times
er day. Patients who underwent prophylactic ICD were
ess likely to abstain from driving (p  0.04).
Over a median follow-up of 562 days (interquartile range
75 to 882 days), 414 total ICD shocks occurred in the
,188 patients enrolled in the TOVA study. Of these, 324
74.6%) were for VT or VF translating into an absolute risk
f experiencing a shock for VT or VF of 1 per 56,260
erson-hours spent in the study. The post-shock interview
as completed within 72 h for 272 of these shocks (66%)
ccurring among 161 patients. Of these 272 shocks, 113
atients (70.2%) received 1 shock, 22 patients (13.6%)
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Driving and ICD Shocks for VT/VF December 4, 2007:2233–40eceived 2 shocks, 16 (9.9%) patients received 3 to 4 shocks,
nd 10 patients (6.2%) received more than 4 shocks.
nformation on exposure to driving was available for 259 of
hese shocks (95%), and these events were included in the
ase-crossover analysis.
Of the 259 total ICD shock episodes included in the
nalysis, 193 (74.5%) were documented to be for an
pisode of VT or VF, of which 44 (22.8%) occurred
ithin 1 h of driving a car among 23 patients. Of these
hocks, 8 were preceded by lightheadedness and 3 re-
ulted in syncope. Using the case-crossover method, the
R of an ICD shock for VT/VF within 1 h of driving was
levated at 2.24 (95% confidence interval [CI] 1.57 to
.18, p  0.001) compared with the risk at other times
uring the study. This elevation in the risk seemed to be
pecific for ventricular arrhythmias because there was no
levation in the risk of inappropriate shocks (n  55, RR
1.07, 95% CI 0.49 to 2.33). To put these RRs into
erspective, if one assumes that the 2.24-fold elevation in
isk observed in the case-crossover analysis was general-
aseline Clinical Characteristics by Reported Driving Status
Table 1 Baseline Clinical Characteristics by Reported Driving S
Variable <1 Time per Week 1 to
Number of participants (N  1,106) 224
Mean age (SD), yrs 66.8 (13.3)
Female gender 80 (35.7)
Caucasian 163 (73.1)
Greater than a high school education 93 (42.1)
Smoking
Never 69 (30.8)
Past 131 (58.5)
Current 24 (10.7)
Physical activity more than once per week† 119 (53.1)
Diabetes 67 (29.9)
Hypertension 135 (60.3)
Body mass index 30 kg/m2 67 (30.3)
Coronary artery disease 166 (74.4)
Congestive heart failure 123 (55.9)
LVEF 30% 84 (40.4)
Indication for device implantation
Cardiac arrest 73 (33.2)
Sustained VT 65 (29.6)
Syncope with inducible VT 28 (12.7)
Nonsustained VT/prophylactic 54 (24.6)
ICD implantation within 6 months 58 (26.2)
Prior ICD discharge 36 (16.1)
Medications
Beta-blocker 131 (58.5)
Digoxin 87 (38.8)
Diuretics 130 (58.0)
ACE inhibitors/ARB 88 (39.3)
Statin 75 (33.5)
Amiodarone 60 (26.8)
Data are expressed as number (%) unless otherwise indicated. †Moderate and vigorous, defined
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; ICD  implantablezable to the entire cohort, this would still translate into plow overall absolute risk of ICD shock for VT/VF (1
pisode per 25,116 person-hours spent driving).
We then examined the RR of VT/VF within 3 compo-
ents of the hazard period (Fig. 1): the period during
riving (A), the first 30-min interval (B), and the second
0-min interval (C) after a driving episode. Of the 44 ICD
hocks for VT/VF that occurred within 1 h of driving, 7
ccurred during driving, 30 occurred 30 min immediately
fter driving, and 7 occurred in the last 30-min period.
hen these hazard periods were examined separately, the
isk of VT/VF was only significantly elevated in the 30-min
eriod immediately after an episode of driving (RR 4.46,
5% CI 2.92 to 6.82, p  0.001). Importantly, the risk of
T/VF was not significantly elevated during an episode of
riving (RR 1.05, 95% CI 0.48 to 2.30). In addition, none
f the shocks for VT or VF that occurred during driving
esulted in lightheadedness or syncope, and only 1 resulted
n an automobile accident.
We then repeated the aforementioned case-crossover
nalysis only including the first shock experienced by each
Frequency of Driving*
es per Week Daily 2 or More Times per Day p Value
88 228 465
(11.9) 65.1 (11.0) 61.9 (12.7) 0.001
(26.6) 28 (12.3) 72 (15.5) 0.001
(86.7) 210 (92.1) 434 (93.3) 0.001
(48.7) 102 (45.5) 275 (60.4) 0.001
(26.0) 41 (18.0) 119 (25.7) 0.13
(60.6) 157 (68.8) 297 (64.0) 0.11
(12.8) 30 (13.2) 48 (10.3) 0.72
(61.7) 162 (70.7) 344 (74.1) 0.001
(19.2) 46 (20.4) 93 (20.1) 0.02
(52.9) 124 (54.9) 232 (50.1) 0.02
(28.8) 64 (28.7) 147 (31.8) 0.60
(72.3) 181 (80.1) 323 (70.5) 0.37
(47.6) 102 (45.3) 179 (39.2) 0.001
(42.9) 81 (37.9) 138 (31.9) 0.01
(30.4) 62 (27.7) 119 (26.3) 0.05
(34.8) 67 (29.9) 139 (30.7) 0.91
(11.1) 29 (13.0) 55 (12.1) 0.97
(23.8) 66 (29.5) 140 (30.9) 0.04
(20.7) 47 (20.8) 90 (19.7) 0.08
(17.6) 72 (31.6) 59 (12.7) 0.32
(52.7) 154 (67.5) 294 (63.2) 0.05
(35.6) 69 (30.3) 152 (32.7) 0.09
(49.5) 103 (45.2) 187 (40.2) 0.001
(38.3) 109 (47.8) 161 (34.6) 0.28
(36.2) 98 (43.0) 173 (37.2) 0.31
(22.3) 50 (21.9) 95 (20.4) 0.08
metabolic equivalents.
verter-defibrillator; LVEF  left ventricular ejection fraction; VT  ventricular tachycardia.tatus
6 Tim
1
64.8
50
163
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42atient to evaluate how repeated shocks in the same patient
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December 4, 2007:2233–40 Driving and ICD Shocks for VT/VFay have influenced the results. In this sensitivity analysis,
he results for all analyses remained essentially unchanged.
he RR of ICD shock for VT/VF within 1 h of driving was
till elevated at 2.25 (95% CI 1.38 to 3.66), and the risk
ontinued to be confined to the 30-min period following
riving (RR 4.27, 95% CI 2.36 to 7.75) rather than during
he driving episode itself (RR 1.31, 95% CI 0.50 to 3.46).
gain there was no elevation in the risk of inappropriate
CD shocks during or after driving.
To explore the possibility that the delayed elevation in
isk of VT/VF could be attributable to another triggering
ctivity linked in time to driving, we examined the specific
ctivity participants were engaged in at the time of ICD
hock for those that occurred in the 30-min hazard period
fter driving. This examination revealed 7 episodes (23.3%)
n which patients were engaged in physical exertion of at
east 5 METs at the time of ICD discharge for VT/VF as
ompared with 15 episodes among those not exposed to
riving in the 30 min before the ICD shock (9.9%; p 
.05). Those shocked within the 30-min period after driving
ere also more likely to have experienced at least moderate
evels of anger as compared with those who were not (13.3%
s. 4.2%; p  0.07). Therefore, we performed a sensitivity
nalysis that excluded all shocks during which the partici-
ant was exposed to moderate levels of exertion (5 METs)
r anger within 1 h before the shock (n  44). In this
nalysis, the RR within 1 h of driving was essentially
nchanged (RR 1.95, 95% CI 1.29 to 2.96, p  0.002) and
he delayed peak in risk at 30 min was attenuated but
emained significant (RR 3.41, 95% CI 2.02 to 5.78, p 
.001). With respect to other activities participants were
ngaged in at the time of shock, none of these seemed to be
nown triggers. Specifically, 6 occurred before or during a
eal and another 5 occurred during shopping. The remain-
er (n  11) occurred at rest.
Because several studies have reported nadirs in the inci-
ence of ICD shocks during the nighttime sleeping hours
etween 12 AM and 6 AM (19,20), and because patients are
nlikely to drive during these sleeping hours, we performed
sensitivity analysis excluding this time period from the
ase-crossover analysis. Again, the RR within 1 h of driving
emained significantly elevated (RR 1.93, 95% CI 1.35 to
.77, p  0.001) and the delayed peak in risk at 30 min was
till present (RR 4.24, 95% CI 2.71 to 6.62, p  0.001).
We then explored our data for possible effect modifica-
ion using stratified analyses (Table 2). None of the poten-
ial modifiers outlined in Table 2 reached statistical signif-
cance; however, our power to detect such interactions was
imited. There was a weak trend for patients with recent
mplants (6 months) and those who had experienced prior
CD discharges to have a higher risk of ICD shock for
T/VF within 1 h of driving. There was no apparent
ifference in the risk elevation for those who had their ICD
mplanted as secondary or primary prevention. Interestingly,
atients with a higher baseline left ventricular ejection
raction and those without congestive heart failure also pended to be at higher risk. Of note, there was no evidence
hat beta-blockers significantly modified risk.
iscussion
n this multicenter prospective cohort of 1,188 patients with
CDs, 80% of all participants and 75% of those within 6
onths of their implantation reported driving a car at least
nce per week. Among participants who received ICD
hocks, an ICD shock for VT or VF was twice as likely to
ccur within 1 h of driving a car as compared with during
ther activities or rest (RR 2.24, 95% CI 1.57 to 3.18, p 
.001). This elevation in risk occurred primarily during the
0-min period after driving rather than during the driving
pisode itself and also seemed to be specific for ICD shocks
ttributable to VT/VF.
To our knowledge, our study is the first to examine the
ssociation between driving a car and the onset of ventric-
lar arrhythmias. These results for ventricular arrhythmias
n ICD patients are roughly consistent with the 2.9-fold
ncreased risk of MI observed within 1 h of exposure to
raffic reported in a recent case-crossover study (9). This
rior study also found the risk to be higher after compared
o during the exposure, and the majority of the exposure to
raffic was through riding in cars. It was unknown whether
he participants were driving or were passengers in cars
hen exposed, but elevated risks of MI also were noted after
xposure to public transportation, suggesting that the asso-
iation may not be entirely attributable to the driving act
tself. Because we did not collect information on average
ime spent as a passenger in a car, we do not know whether
he risk of VT/VF would be similarly elevated if the
articipants in our study were not driving.
This delayed elevation in risk found in both studies might
e explained if an induction effect or activation of an
ntermediary mechanism were required to precipitate ven-
ricular arrhythmias or MI. Alternatively, driving might
ncrease the susceptibility to other triggering activities.
erturbations of the autonomic nervous system by stress or
nger brought on by driving and/or exposure to particulate
ir pollution are possible mechanisms that could potentially
nderlie both of the observed associations. Exposure to
articulate matter, which is estimated to be 2-fold greater
hile riding in a car than on a bike (4), has been consistently
ssociated with short-term (minutes) and longer-term
hours) reductions in heart rate variability compatible with
ithdrawal of vagal tone (22–24). The resulting imbalance
n autonomic tone could then lead to an increased suscep-
ibility to ventricular arrhythmias or to acute plaque rupture
nd/or thrombosis (25).
In addition to the possible mechanistic implications,
here are also clinical and public health implications of these
ata. First, in this multicenter study, although the amount
f time ICD patients spent driving was somewhat lower
han estimates for the general population (2.3% vs. 4.0% of
erson-time, respectively) (1,26), most patients resumed
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Driving and ICD Shocks for VT/VF December 4, 2007:2233–40riving within 6 months of ICD implantation. Despite
uidelines recommending a period of abstention from driv-
ng after an episode of life-threatening ventricular arrhyth-
ia (1,26,27), the majority of patients do not comply with
his recommendation (13,28–30). The observed trends
oward higher risks of ICD shock for VT/VF among
atients with recent implants and prior discharges in asso-
iation with driving concur with guidelines (1,26,27).
It is important to emphasize that the RR was not
ignificantly elevated during the driving episode. Therefore,
he absolute risk of experiencing an ICD shock for VT/VF
uring driving should be similar to that observed at other
imes, which in this population was quite low (1 per 56,260
Potential Modifiers of the Risk of an ICD Shockfor VT/VF Associated With an Acute Episode of
Table 2 Potential Modifiers of the Risk of afor VT/VF Associated With an Acut
Modifier
Episodes
of VT/VF
Exposed
Driving
Age, yrs
55 39 8
55–69 88 24
70 66 12
Gender
Men 171 39
Women 22 5
Education
Less than high school 33 1
High school 48 12
More than high school 112 31
Employment status
Employed 63 23
Unemployed 104 18
ICD implant within 6 months
Yes 56 16
No 137 28
LVEF 30%
Yes 92 18
No 96 24
Congestive heart failure
Yes 108 19
No 84 24
Coronary heart disease
Yes 152 34
No 40 9
Diabetes
Yes 48 13
No 145 31
Primary prevention ICD
Yes 57 13
No 134 30
History of prior ICD discharge
Yes 115 32
No 78 12
On beta-blockers
Yes 129 32
No 64 12
VF  ventricular fibrillation; other abbreviations as in Table 1.erson-hours spent in the study). Based on these data, priving among ICD patients would not be expected to
ranslate into a significant excess risk of injury to the patient
r society from automobile accidents. In agreement with
his postulated low absolute risk, there was only 1 shock for
T/VF during driving that resulted in an automobile
ccident in this cohort. Other studies using differing meth-
dologies have come to similar conclusions (13,30).
There are several limitations to our study. Our observa-
ional study cannot prove causality, and the association
etween driving and ICD shock for VT/VF could, at least
n part, be caused by another activity or exposure that is
ssociated in time with driving. From our limited examina-
ion of the types of activities patients were engaged in,
ng
Shock
sode of Driving
Relative Risk (95% Confidence Interval)
of VT/VF Associated With Acute
Episode of Driving p Value
1.93 (0.79–4.69) 0.86
2.17 (1.38–3.41)
2.60 (1.29–5.24)
2.07 (1.43–3.01) 0.18
4.66 (1.51–14.4)
0.53 (0.08–3.56) 0.20
3.38 (1.49–7.65)
2.30 (1.54–3.44)
2.38 (1.48–3.92) 0.79
2.17 (1.22–3.85)
3.80 (1.83–7.90) 0.09
1.86 (1.24–2.79)
1.50 (0.89–2.52) 0.06
3.04 (1.82–5.08)
1.58 (0.95–2.61) 0.08
3.02 (1.81–5.04)
2.11 (1.43–3.12) 0.71
2.49 (1.05–5.89)
2.19 (1.28–3.73) 0.93
2.26 (1.44–3.54)
2.44 (1.18–5.06) 0.69
2.09 (1.39–3.14)
2.78 (1.84–4.20) 0.10
1.45 (0.74–2.83)
2.30 (1.54–3.43) 0.79
2.06 (1.00–4.23)Drivi
n ICD
e Epi
toossible associations between driving and subsequent expo-
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December 4, 2007:2233–40 Driving and ICD Shocks for VT/VFure to exertion and anger were found. In sensitivity analyses
xcluding ICD shocks during which the participant was also
xposed to exertion or anger, the delayed elevation in risk
as attenuated slightly but remained elevated, suggesting
hat these activities do not explain the entire association
etween driving and ICD shocks for VT/VF. Also, if
atients tended to drive at certain times of the day, circadian
ariations in risk of VT/VF could account for part of the
ssociation observed. However, the relationships persisted
hen nighttime hours were excluded from the analysis, and
he discrete increase in risk in the 30-min period after
riving without any elevation in the risk during driving
ould be difficult to explain on the basis of circadian
ariation alone.
Another limitation of our data is that the assessment of
riving was by self-report and was not anonymous. Patients
ay have been less likely to report that a shock occurred
hile driving for fear that driving privileges would be
urtailed, which could lead to an underestimation of the risk
uring driving. Also, if a patient were driving against
edical advice, he or she may tend to minimize estimates of
riving at baseline and follow-up interviews, which could
ead to an overestimation of the risk. However, given the
igh frequency of reported driving in this cohort, severe
nderreporting is unlikely. Furthermore, not all patients
esumed driving, and those who did tended to be healthier.
herefore, these results may not apply to all patients with
CDs.
Finally, although we made every attempt to obtain
nterview data on all patients within 72 h of the ICD shock,
his proved to be difficult when patients failed to alert the
articipating center when a shock occurred. If the activity at
he time of shock influenced whether the patient noticed or
eported a shock, this could also potentially bias our risk
stimates. This seems most plausible for shocks that
ight have occurred during sleep and thus gone unno-
iced. However, the percentage of shocks that occurred
etween the hours of midnight to 6 AM was slightly
reater among those with interview data versus those
ithout (15.0% vs. 11.2% respectively, p  0.24), which
rgues against this possibility.
In summary, these prospective data in a large multicenter
ohort of patients with ICDs suggest that the risk of VT or
F is transiently increased in the 30-min period after
riving in susceptible patients. The lack of elevation in risk
uring the driving episode, along with the expected low
bsolute risk, provides some reassurance that driving by
CD patients should not translate into an important rate of
ersonal or public injury. The mechanism behind the
elayed effect is unclear and may imply an induction effect
nd/or synergistic effects with other triggers. Whether these
isks would extend to other patient populations or to the
eneral population is unknown, and further study is required
o evaluate the underlying mechanisms.eprint requests and correspondence: Dr. Christine M. Albert,
enter for Arrhythmia Prevention, Division of Preventive Medi-
ine and Cardiovascular Division, Brigham and Women’s Hospi-
al, 900 Commonwealth Avenue East, Boston, Massachusetts
2215-1204. E-mail: calbert@partners.org.
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